Skip to content

Don Koelpin

Compass Pathways, London (Kirlić, Lennard-Jones, Atli, Malievskaia, Gaillard, Goodwin, Koelpin); Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Modlin); School of Medicine, University of California San Diego, San Diego (Peck).

2 papers in the library · 29 citations · publishing 2025

Papers

Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions

American Journal of Psychiatry January 1, 2025 Namik Kirlić, Molly Lennard-Jones, Merve Atli et al. 27 citations

A structured framework called the Compass Psychological Support Model (CPSM) provides psychological support for individuals with treatment-resistant depression receiving investigational psilocybin treatment in clinical trials. The model aims to ensure a safe and meaningful psychedelic experience and enables future research into which aspects of psychological support or psychotherapy best complement psilocybin treatment. The authors describe therapist training, mentoring, and fidelity assessment programs developed to maintain quality and consistency in delivering the CPSM.

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.

EClinicalMedicine December 1, 2025 Nadav Liam Modlin, Victoria Williamson, Guy M Goodwin et al. 2 citations

Psilocybin treatment for post-traumatic stress disorder, when delivered with standardized preparation and support, may allow patients to engage with trauma-related material indirectly through affective, somatic, and self-transcendent experiences, such as feelings of unity or dissolution of self, rather than requiring direct confrontation with traumatic memories as in standard therapies. This qualitative study, nested within a phase 2 trial involving 21 adults with PTSD, identified four core themes: non-pharmacological factors for psychological safety and trust, the experiential nature of psilocybin treatment, engagement with trauma-related material, and comparative reflections on prior therapies. The findings suggest psilocybin offers a meaningful therapeutic opportunity, but larger controlled studies are needed.